Your browser doesn't support javascript.
loading
Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska, Joanna M; Palmer, Joanne; Morisset, Valerie; Giblin, Gerard Mp; Obermann, Mark; Ettlin, Dominik A; Cruccu, Giorgio; Bendtsen, Lars; Estacion, Mark; Derjean, Dominique; Waxman, Stephen G; Layton, Gary; Gunn, Kevin; Tate, Simon.
Afiliação
  • Zakrzewska JM; Facial Pain Unit, Division of Diagnostic, Surgical and Medical Sciences, Eastman Dental Hospital, University College London Hospitals NHS Foundation Trust/University College London, London, UK. Electronic address: j.zakrzewska@ucl.ac.uk.
  • Palmer J; Convergence Pharmaceuticals, Cambridge, UK.
  • Morisset V; Convergence Pharmaceuticals, Cambridge, UK.
  • Giblin GM; Convergence Pharmaceuticals, Cambridge, UK.
  • Obermann M; Department of Neurology and German Headache Center, University of Duisburg-Essen, Essen, Germany; Center for Neurology, Asklepios Hospitals Schildautal, Seesen, Germany.
  • Ettlin DA; Interdisciplinary Orofacial Pain Unit, Clinic KFS-KAB, Center of Dental Medicine, University of Zurich, Zurich, Switzerland.
  • Cruccu G; Department of Neurology and Psychiatry, Sapienza University, Roma, Italy.
  • Bendtsen L; Danish Headache Centre, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Nordre Ringvej 67, 2600 Glostrup, Denmark.
  • Estacion M; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, and Veterans Affairs Medical Center, West Haven, CT, USA.
  • Derjean D; Convergence Pharmaceuticals, Cambridge, UK.
  • Waxman SG; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, and Veterans Affairs Medical Center, West Haven, CT, USA.
  • Layton G; ParamStat, Ash, Canterbury, Kent, UK.
  • Gunn K; Convergence Pharmaceuticals, Cambridge, UK.
  • Tate S; Convergence Pharmaceuticals, Cambridge, UK.
Lancet Neurol ; 16(4): 291-300, 2017 Apr.
Article em En | MEDLINE | ID: mdl-28216232
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuralgia do Trigêmeo / Resultado do Tratamento / Bloqueadores dos Canais de Sódio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuralgia do Trigêmeo / Resultado do Tratamento / Bloqueadores dos Canais de Sódio Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2017 Tipo de documento: Article País de publicação: Reino Unido